Frazier Life Sciences
VC Fund
Seattle, United States
Frazier Life Sciences is a VC fund in Seattle focused on Biotechnology and Health Care. Frazier Life Sciences IX is a venture capital fund. Frazier Life Sciences invests in and builds companies developing and commercializing novel therapeutics at all stages, from company formation to public.
- Total investments:
- 60
- Last investment:
- Lead investor:
- 28%
Last updated:
For AI agents: llms.txt
Industries Frazier Life Sciences invests in
Stages Frazier Life Sciences invests in
Countries Frazier Life Sciences invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Tao Fu
|
|||
4 more contacts available
Investment Focus
Industry
- Biotechnology 34 (57%)
- Health Care 23 (38%)
- Therapeutics 16 (27%)
- Pharmaceutical 14 (23%)
- Medical 11 (18%)
Stage
- Post-IPO Equity 24 (40%)
- Series B 7 (12%)
- Series A 6 (10%)
- Series C 6 (10%)
- Series D 2 (3%)
Country
- United States 29 (48%)
- United Kingdom 3 (5%)
- Canada 2 (3%)
- China 1 (2%)
- Sweden 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Tao Fu
Venture Partner
|
Venture Partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Maze Therapeutics
|
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.andits also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases. | $150M / Post-IPO Equity / Apr 22, 2026 | |
Egetis Therapeutics
|
Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development. | $38.3M / Post-IPO Equity / Apr 21, 2026 | |
Angitia Biopharmaceuticals
|
Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. | $130M / Series D / Feb 05, 2026 | |
Parabilis Medicines
|
Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $305M / Series F / Jan 08, 2026 | |
Diagonal Therapeutics
|
Diagonal Therapeutics is a biotechnology startup that is pioneering a novel technique to finding and producing agonist antibodies. Diagonal Therapeutics platform combines novel computational and experimental methodologies to solve the traditional obstacles associated with agonist antibody drug development. | $125M / Series B / Jan 08, 2026 | |
Xilio Therapeutics
|
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of provenimmuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines.These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatmentXilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States. | $35.8M / Post-IPO Equity / Dec 31, 2025 | |
Aspen Neuroscience
|
Aspen Neuroscience is a development stage and private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. It is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmetmedical needs, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson's disease (PD) and extending across the brain and affected organs. | $115M / Series C / Nov 20, 2025 | |
Tubulis
|
Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $400.6M / Series C / Oct 15, 2025 | |
|
Maze Therapeutics
|
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.andits also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases. | $150M / Post-IPO Equity / Sep 11, 2025 | |
Crescent Biopharma
|
Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines targeting verified biology to improve care for patients with solid tumors. | $200M / Post-IPO Equity / Jun 16, 2025 | |
| See all 60 investments → | |||
Co-Investors
Janus Henderson Investors
17 deals together
Deep Track Capital
14 deals together
Logos Capital
14 deals together
RA Capital Management
13 deals together
Venrock Healthcare Capital Partners
12 deals together
Biotechnology Value Fund
11 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Frazier Life Sciences invest in?
Frazier Life Sciences invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series B stage. Most of the 60 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Frazier Life Sciences?
Public channels for Frazier Life Sciences include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Frazier Life Sciences?
The team at Frazier Life Sciences includes Tao Fu (Venture Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
